MedTrace Logo

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-12-18

Study results available
· View outcomes & findings →

Summary

The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.

Conditions

Interventions

DRUG

Talimogene Laherparepvec

Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection

Sponsors & Collaborators

  • Symbion Research International

    collaborator INDUSTRY

  • BioVex Limited

    lead INDUSTRY

Principal Investigators

  • John Nemunaitis, MD · Mary Crowley Medical Research Center

  • Rob Coffin, PhD · BioVex Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-12-31
Completion
2009-05-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289016 on ClinicalTrials.gov